Role of Parasitic Infection in Inflammatory Bowel Disease and Irritable Bowel Syndrome

Role of parasitic infection in Inflammatory bowel disease and Irritable bowel The burden of the parasitic disease is in-direct relation with the health and nutritional status of the host, inducing not only parasite-specific immunity but also can modify the host's immune responses . Many parasites can imitate inflammatory bowel disorders and some studies showed that infection with parasites can improve disorders like IBD or moderate the symptoms of inflammatory bowel disorders . Even though, many studies have shown that gastrointestinal infection is an important risk factor for the development of IBS

Study Overview

• Status: Recruiting
• Conditions: Parasite IBS IBD

Detailed Description

1. Detect the prevalence of parasite/s associated with Inflammatory bowel diseases (IBD) and Irritable bowel syndrome (IBS) in comparison with control subjects.
2. Evaluating the effect of the parasite on the course and prognosis of the diseases.
3. Evaluating the effect of the antiparasitic drugs on the course and prognosis of the diseases.

• Study Type: Observational
• Enrollment (Anticipated): 300

Contacts and Locations

• Study Contact: Name: marina shawqi, md; Phone Number: 01276121351; Email: gm161059@gmail.com
• Study Contact Backup: Name: lamia galal; Phone Number: 01003143075; Email: lamiazak@gmail.com

Study Locations

• Egypt
  • Assiut, Egypt
    • Recruiting
    • Marina Gamil Shwqi
    • Contact: lamia galal; Phone Number: +201003143075; Email: lamiazak@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 17 years to 69 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Diagnosis of IBD will be confirmed using standard clinical, endoscopic, radiographic and pathological criteria according to the Montreal classification of the extent and severity of IBD The activity of the disease will be measured using the Mayo Clinic score consisting of 4 items: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and patient's functional assessment Diagnosis of IBS will depend on Rome IV criteria Recurrent abdominal pain on average at least 1 day/week in the last 3 months, associated with two or more of the following criteria: Related to defecation; Associated with a change in the frequency of stool and/ or Associated with a change in the form (appearance) of stool.

• any patient who received antipiotic or antiparasitic drug within the past 4 weeks not taken

Description

Inclusion Criteria:

• Diagnosis of IBD will be confirmed using

  1. standard clinical,
  2. endoscopic,
  3. radiographic and4 pathological criteria according to the Montreal classification of the extent and severity of IBD

• Diagnosis of IBS will depend on Rome IV criteria

  1. Recurrent abdominal pain on average at least 1 day/week in the last 3 months,
  2. associated with two or more of the following criteria:
  3. Related to defecation;
  4. Associated with a change in the frequency of stool and/ or Associated with a change in the form (appearance) of stool.

Exclusion Criteria:

• any patient who received antipiotic or antiparasitic drug within the past 4 weeks

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort
IBD GROUPS; PATIENT WITH IBD DISEASE
IBS GROUP; PATIENT WIT IBS DISEASE
CONTROL 1; CONTROL WITH POSITIVE PARASITIC INFECTION AN POSITIVE GIT SYMTOMS
CONTROL2; HEALTHY VOLUNTEARS

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Detect the prevalence of parasite/s associated with Inflammatory bowel diseases (IBD) and Irritable bowel syndrome (IBS) in comparison with control subjects.	Detect the prevalence of parasite/s associated with Inflammatory bowel diseases (IBD) and Irritable bowel syndrome (IBS) in comparison with control subjects.by making stool analysis and clinical examination	baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
measure the effect of the antiparasitic drugs on the course and prognosis of the diseases	giving the patient antiparasitic drug and measure the effect of anti parasitic drug on course and prognosis of disease	baseline

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Principal Investigator: rasha hassan, Assiut University; Principal Investigator: mona mostafa, Assiut University

Publications and helpful links

Helpful Links

• Human Intestinal Parasites
• Comparative pathobiology of the intestinal protozoan parasites giardia lamblia, entamoeba histolytica, and cryptosporidium parvum
• Opportunistic infections due to inflammatory bowel disease therapy
• Prevalence of Intestinal Parasitic Infections among the Bulgarian Population Over a Three Year Period
• Soil-transmitted helminth infections: updating the global picture
• Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer
• Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2021
• Primary Completion (Anticipated): June 1, 2024
• Study Completion (Anticipated): June 1, 2024

Study Registration Dates

• First Submitted: February 5, 2021
• First Submitted That Met QC Criteria: February 15, 2021
• First Posted (Actual): February 18, 2021

Study Record Updates

• Last Update Posted (Actual): February 18, 2021
• Last Update Submitted That Met QC Criteria: February 15, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Infections; Gastrointestinal Diseases; Gastroenteritis; Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Irritable Bowel Syndrome; Inflammatory Bowel Diseases; Parasitic Diseases
• Other Study ID Numbers: role of parasites in ibd ibs

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No